FDA OKs anti-wrinkle drug, a longer-lasting Botox competitor
The Food and Drug Administration (FDA) on Thursday approved the anti-wrinkle injection Daxxify, setting up competition for Botox, which has dominated the market for two decades. Manufacturer Revance Therapeutics said its studies show the drug can temporarily improve moderate to severe frown lines for about six months, almost twice as long a period as Botox....